未知生产厂商
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
Axatilimab is a high affinity antibody targeting the colony stimulating factor 1 receptors (CSF-1R). Its actions at CSF-1R allows for the regulation of the expansion and infiltration of donor-derived macrophages that mediate chronic graft versus host disease.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
